Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 8 |
List of Tables | 8 | 1 |
List of Figures | 9 | 1 |
Introduction | 10 | 1 |
Global Markets Direct Report Coverage | 10 | 1 |
Refractory Chronic Lymphocytic Leukemia (CLL) Overview | 11 | 1 |
Therapeutics Development | 12 | 2 |
Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) Overview | 12 | 1 |
Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) Comparative Analysis | 13 | 1 |
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies | 14 | 2 |
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
Refractory Chronic Lymphocytic Leukemia (CLL) Pipeline Products Glance | 17 | 3 |
Late Stage Products | 17 | 1 |
Clinical Stage Products | 18 | 1 |
Early Stage Products | 19 | 1 |
Refractory Chronic Lymphocytic Leukemia (CLL) Products under Development by Companies | 20 | 3 |
Refractory Chronic Lymphocytic Leukemia (CLL) Products under Investigation by Universities/Institutes | 23 | 1 |
Refractory Chronic Lymphocytic Leukemia (CLL) Companies Involved in Therapeutics Development | 24 | 30 |
4SC AG | 24 | 1 |
AbbVie Inc | 25 | 1 |
Arno Therapeutics, Inc. | 26 | 1 |
Astellas Pharma Inc. | 27 | 1 |
Astex Pharmaceuticals Inc | 28 | 1 |
Boehringer Ingelheim GmbH | 29 | 1 |
Bristol-Myers Squibb Company | 30 | 1 |
Celgene Corporation | 31 | 1 |
Cellular Biomedicine Group, Inc. | 32 | 1 |
F. Hoffmann-La Roche Ltd. | 33 | 1 |
Gilead Sciences, Inc. | 34 | 1 |
Hutchison MediPharma Limited | 35 | 1 |
ImmunoGen, Inc. | 36 | 1 |
Immunomedics, Inc. | 37 | 1 |
Incyte Corporation | 38 | 1 |
Innate Pharma S.A. | 39 | 1 |
Juno Therapeutics Inc. | 40 | 1 |
Karyopharm Therapeutics, Inc. | 41 | 1 |
LFB S.A. | 42 | 1 |
Lymphocyte Activation Technologies, S.A. | 43 | 1 |
Medicenna Therapeutics, Inc. | 44 | 1 |
Millennium Pharmaceuticals Inc | 45 | 1 |
MorphoSys AG | 46 | 1 |
Novartis AG | 47 | 1 |
Oncternal Therapeutics, Inc. | 48 | 1 |
Ono Pharmaceutical Co., Ltd. | 49 | 1 |
Portola Pharmaceuticals, Inc. | 50 | 1 |
Sanofi | 51 | 1 |
Tragara Pharmaceuticals, Inc. | 52 | 1 |
Verastem, Inc. | 53 | 1 |
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Assessment | 54 | 12 |
Assessment by Monotherapy Products | 54 | 1 |
Assessment by Combination Products | 55 | 1 |
Assessment by Target | 56 | 3 |
Assessment by Mechanism of Action | 59 | 3 |
Assessment by Route of Administration | 62 | 2 |
Assessment by Molecule Type | 64 | 2 |
Drug Profiles | 66 | 184 |
(dezapelisib + itacitinib adipate) Drug Profile | 66 | 1 |
4SC-202 Drug Profile | 67 | 2 |
acalabrutinib Drug Profile | 69 | 3 |
ACP-319 Drug Profile | 72 | 1 |
afuresertib hydrochloride Drug Profile | 73 | 3 |
AGS-67E Drug Profile | 76 | 2 |
AR-42 Drug Profile | 78 | 2 |
AT-7519 Drug Profile | 80 | 3 |
atezolizumab Drug Profile | 83 | 14 |
BI-836826 Drug Profile | 97 | 2 |
BMS-986016 Drug Profile | 99 | 2 |
buparlisib hydrochloride Drug Profile | 101 | 5 |
CBM-C19.1 Drug Profile | 106 | 1 |
CBM-C20.1 Drug Profile | 107 | 2 |
CC-122 Drug Profile | 109 | 2 |
Cellular Immunotherapy for Chronic Lymphocytic Leukaemia Drug Profile | 111 | 1 |
Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia Drug Profile | 112 | 1 |
cerdulatinib Drug Profile | 113 | 3 |
duvelisib Drug Profile | 116 | 10 |
HMPL-523 Drug Profile | 126 | 2 |
idelalisib Drug Profile | 128 | 8 |
IMGN-529 Drug Profile | 136 | 2 |
IMMU-114 Drug Profile | 138 | 2 |
JCAR-014 Drug Profile | 140 | 3 |
JCAR-015 Drug Profile | 143 | 4 |
lirilumab Drug Profile | 147 | 4 |
MDNA-56 Drug Profile | 151 | 1 |
monalizumab Drug Profile | 152 | 3 |
MOR-208 Drug Profile | 155 | 5 |
nivolumab Drug Profile | 160 | 26 |
obinutuzumab Drug Profile | 186 | 7 |
PCAR-019 Drug Profile | 193 | 1 |
PCAR-119 Drug Profile | 194 | 1 |
pilaralisib Drug Profile | 195 | 3 |
S-055746 Drug Profile | 198 | 1 |
selinexor Drug Profile | 199 | 19 |
spebrutinib besylate Drug Profile | 218 | 2 |
TAK-659 Drug Profile | 220 | 1 |
TG-02 Drug Profile | 221 | 3 |
tisagenlecleucel-T Drug Profile | 224 | 5 |
ublituximab Drug Profile | 229 | 7 |
UC-961 Drug Profile | 236 | 2 |
ulocuplumab Drug Profile | 238 | 1 |
urelumab Drug Profile | 239 | 2 |
venetoclax Drug Profile | 241 | 9 |
Refractory Chronic Lymphocytic Leukemia (CLL) Dormant Projects | 250 | 2 |
Refractory Chronic Lymphocytic Leukemia (CLL) Discontinued Products | 252 | 1 |
Refractory Chronic Lymphocytic Leukemia (CLL) Product Development Milestones | 253 | 12 |
Featured News &Press Releases | 253 | 1 |
Apr 18, 2016: Immunomedics Announces Potent Anti-Tumor Activities with IMMU-114 in Preclinical Study in Acute and Chronic Leukemia | 253 | 1 |
Jan 20, 2016: Abbvie's Venetoclax Receives Breakthrough Therapy Designation From FDA In Combination With Rituximab For The Treatment Of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia | 253 | 1 |
Nov 05, 2015: Genentech to Present New Clinical Data From Venetoclax at American Society of Hematology 2015 Annual Meeting | 254 | 1 |
Jun 12, 2015: Phase 1b Study of Investigational Treatment Venetoclax With Rituximab Shows Clinical Response in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia | 255 | 1 |
Jun 11, 2015: TG Therapeutics to Present Clinical Data on TG-1101 in combination with ibrutinib at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma | 256 | 1 |
May 11, 2015: Abbvie To Present New Data From Studies Of Duvelisib Assets In Multiple Cancers At The 51st American Society Of Clinical Oncology Annual Meeting | 256 | 1 |
May 06, 2015: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17P Deletion Genetic Mutation | 257 | 1 |
Dec 05, 2014: Roche to present clinical data on obinutuzumab at ASH | 257 | 1 |
Nov 06, 2014: Infinity Announces Clinical and Preclincal Data for Duvelisib to Be Presented at ASH 2014 Annual Meeting | 258 | 1 |
May 31, 2014: AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting | 259 | 1 |
Apr 23, 2014: Abbvie To Present Data On ABT-199 At The 2014 American Society Of Clinical Oncology Annual Meeting | 260 | 1 |
Dec 03, 2013: MorphoSys Strengthens European Patent Position on anti-CD19 Cancer Program MOR208 | 260 | 1 |
Oct 22, 2013: MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208 | 261 | 1 |
Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 | 261 | 1 |
Jun 17, 2013: AbbVie Presents Preliminary Results From Phase I Study Of ABT-199/GDC-0199 In Patients With High-Risk CLL At EHA Annual Meeting | 262 | 3 |
Appendix | 265 | 2 |
Methodology | 265 | 1 |
Coverage | 265 | 1 |
Secondary Research | 265 | 1 |
Primary Research | 265 | 1 |
Expert Panel Validation | 265 | 1 |
Contact Us | 265 | 1 |
Disclaimer | 266 | 1 |